Milestone Pharmaceuticals Files 2024 10-K
Ticker: MIST · Form: 10-K · Filed: Mar 13, 2025 · CIK: 1408443
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals
TL;DR
Milestone Pharma's 2024 10-K shows $53.35M assets, $33.48M liabilities. Retained earnings at $12.91M.
AI Summary
Milestone Pharmaceuticals Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company reported total assets of $53.35 million and total liabilities of $33.48 million. Key financial figures include retained earnings of $12.91 million and additional paid-in capital of $95.77 million as of December 31, 2024. The filing also references various stock plans and options, including the Employee Stock Purchase Plan and the Restated Share Option Plan 2011.
Why It Matters
This 10-K filing provides a comprehensive overview of Milestone Pharmaceuticals' financial health and operational status for the past fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company's financial statements indicate a significant amount of liabilities relative to assets, and the nature of pharmaceutical development inherently carries substantial risks.
Key Numbers
- $53.35M — Total Assets (As of December 31, 2024)
- $33.48M — Total Liabilities (As of December 31, 2024)
- $12.91M — Retained Earnings (As of December 31, 2024)
- $95.77M — Additional Paid-in Capital (As of December 31, 2024)
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Filer of the 10-K
- December 31, 2024 (date) — Fiscal year end
- $53.35 million (dollar_amount) — Total assets
- $33.48 million (dollar_amount) — Total liabilities
- $12.91 million (dollar_amount) — Retained earnings as of December 31, 2024
- $95.77 million (dollar_amount) — Additional paid-in capital as of December 31, 2024
- Employee Stock Purchase Plan (company) — Mentioned stock plan
- Restated Share Option Plan 2011 (company) — Mentioned stock plan
FAQ
What was Milestone Pharmaceuticals Inc.'s net income or loss for the fiscal year ended December 31, 2024?
The provided snippet does not explicitly state the net income or loss for the fiscal year ended December 31, 2024. It focuses on balance sheet items like assets, liabilities, retained earnings, and additional paid-in capital.
What is the primary business of Milestone Pharmaceuticals Inc.?
Milestone Pharmaceuticals Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification code.
When was the 10-K filing submitted?
The 10-K filing was submitted on March 13, 2025.
What are the total revenues for the fiscal year ended December 31, 2024?
The provided text does not contain information on total revenues for the fiscal year ended December 31, 2024.
What is the company's principal executive office address?
The company's business and mail address is 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8, H4M 2X6.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 13, 2025 regarding Milestone Pharmaceuticals Inc. (MIST).